CASI Pharmeceuticals

View All
Casi Pharmaceuticals

CASI Pharmaceuticals CEO Ken K. Ren, PhD rang the closing bell at NASDAQ on Thursday, June 11, 2015 4PM.

About Us

CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on China and the U.S.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →


Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium

Download →


Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models

Download →

Receive press releases via email